Get regular updates to your inbox.
A study in mice has identified 865 gene targets of the fragile X mental retardation protein (FMRP) — which is missing in people with fragile X syndrome — including more than 100 linked to autism and intellectual disability (ID). Several FMRP targets associated with…
Zynerba Pharmaceuticals announced plans to open a pivotal clinical trial next year for its cannabidiol (CBD) gel Zygel in fragile X syndrome patients with severe symptoms, a group that showed improvements in a previous Phase 2/3 study.  According…
Allos Pharma has obtained exclusive rights to arbaclofen, a potential treatment for fragile X syndrome. The news comes more than seven years after Seaside Therapeutics decided to stop a clinical trial (NCT01013480) due to resource…
Actinogen Medical announced plans to open a Phase 2 trial of its experimental oral therapy Xanamem in boys with fragile X syndrome early next year. The study, to be called XanaFX and take place in Australia, will be the…
Get regular updates to your inbox.